HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer.

AbstractOBJECTIVE:
To compare the long-term survival outcomes for women with advanced ovarian cancer treated with chemotherapy either before or after surgery (neoadjuvant chemotherapy vs primary cytoreductive surgery) at a single tertiary cancer center.
METHODS:
Retrospective cohort study of 326 patients with Stage IIIC or IV high-grade serous ovarian cancer who received neoadjuvant chemotherapy or primary cytoreductive surgery between 2001 and 2011. Clinical treatments were recorded and 10-year survival rates were measured.
RESULTS:
A total of 183 women (56.1%) underwent primary cytoreductive surgery and 143 women (43.9%) received neoadjuvant chemotherapy. Women who received neoadjuvant chemotherapy were more likely to have no residual disease than those who underwent primary cytoreductive surgery (51.4% vs 41.5%; P = 0.030) but experienced inferior 10-year overall survival (9.1% vs 19.3%; P < 0.001). Among those who had primary cytoreductive surgery, those with no residual disease had superior 10-year overall survival than those who had any evidence of residual disease (36.0% vs 7.2%; P < 0.001).
CONCLUSION:
Among women with advanced ovarian cancer, those who underwent primary cytoreductive surgery had better survival than those who received neoadjuvant chemotherapy. Neoadjuvant chemotherapy should be reserved for those in whom optimal primary cytoreductive surgery is not feasible.
AuthorsSoyoun Rachel Kim, Joanne Kotsopoulos, Ping Sun, Marcus Q Bernardini, Stephane Laframboise, Sarah E Ferguson, Barry Rosen, Steven A Narod, Taymaa May
JournalInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (Int J Gynaecol Obstet) Vol. 153 Issue 3 Pg. 417-423 (Jun 2021) ISSN: 1879-3479 [Electronic] United States
PMID33326624 (Publication Type: Journal Article)
Copyright© 2020 International Federation of Gynecology and Obstetrics.
Topics
  • Adult
  • Aged
  • Carcinoma, Ovarian Epithelial (mortality, pathology, therapy)
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • Cytoreduction Surgical Procedures
  • Female
  • Humans
  • Middle Aged
  • Neoadjuvant Therapy
  • Ovarian Neoplasms (mortality, pathology, therapy)
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: